论文部分内容阅读
目的:探讨血浆microRNA在非小细胞肺癌预后方面的应用价值。方法:收集21例非小细胞肺癌患者的血液标本,检测miRNA-486、miRNA-499在NSCLC中的相对表达量,并分析表达量与临床特征的关系。结果:miRNA-486在NSCLC患者中的相对表达量与临床特征无关;miRNA-499在NSCLC中的相对表达量与性别、年龄、吸烟史、病理类型、病灶大小和淋巴结转移无统计学关联,与TNM分期与分化程度情况有统计学关联(P<0.05)。结论:在NSCLC患者中,miRNA-499可能成为预测NSCLC患者的预后指标。
Objective: To investigate the value of plasma microRNA in the prognosis of non-small cell lung cancer. METHODS: Blood samples from 21 patients with NSCLC were collected and the relative expression levels of miRNA-486 and miRNA-499 in NSCLC were detected. The relationship between expression levels and clinical characteristics was analyzed. Results: The relative expression of miRNA-486 in NSCLC patients was not related to the clinical characteristics. The relative expression of miRNA-499 in NSCLC was not statistically related to gender, age, smoking history, pathological type, lesion size and lymph node metastasis. TNM staging and differentiation were statistically related (P<0.05). Conclusion: In patients with NSCLC, miRNA-499 may be a prognostic indicator for NSCLC patients.